上海市癌症患者化疗所致恶心呕吐的横断面研究

曾铖; 金奕滋; 李婷; 章真; 梁晓华; 唐曦; 刘天舒; 李琦; 沈赞; 姜斌; 王理伟; 张俊; 陈思宇; 周彩存; 高勇; 臧远胜; 李恒宇; 董宇超; 湛先保; 钟薏; 刘苓霜; 秦悦农; 胡夕春; 张剑

doi:10.19401/j.cnki.1007-3639.2023.11.006

您当前的位置：

首页 >

文章列表页 >

上海市癌症患者化疗所致恶心呕吐的横断面研究

论著 | 更新时间：2025-12-31

- 上海市癌症患者化疗所致恶心呕吐的横断面研究
- Chemotherapy-induced nausea and vomiting among cancer patients in Shanghai: a cross-sectional study
- 中国癌症杂志 2023年33卷第11期页码：1009-1017
- 作者机构：
  
  1. 复旦大学附属肿瘤医院肿瘤大内科，复旦大学上海医学院肿瘤学系，上海 200032
  2. 复旦大学附属肿瘤医院Ⅰ期临床试验病房，复旦大学上海医学院肿瘤学系，上海 200032
  3. 复旦大学附属肿瘤医院放射治疗中心，复旦大学上海医学院肿瘤学系，上海市放射肿瘤学重点实验室，上海市放射治疗临床医学研究中心，上海 200032
  4. 复旦大学附属华山医院肿瘤科，上海 200040
  5. 复旦大学附属华东医院肿瘤科，上海 200040
  6. 复旦大学附属中山医院肿瘤内科，上海 200032
  7. 上海交通大学医学院附属第一人民医院肿瘤科，上海 200080
  8. 上海交通大学医学院附属第六人民医院肿瘤内科，上海 200233
  9. 上海交通大学医学院附属第九人民医院肿瘤科，上海 201999
  10. 上海交通大学医学院附属仁济医院肿瘤科，上海 200127
  11. 上海交通大学医学院附属瑞金医院肿瘤科，上海 200025
  12. 上海交通大学医学院附属新华医院肿瘤科，上海 200092
  13. 同济大学附属上海市肺科医院肿瘤科，上海 200433
  14. 同济大学附属东方医院肿瘤科，上海 200120
  15. 海军军医大学第二附属医院肿瘤科，上海 200070
  16. 海军军医大学第一附属医院甲乳外科，上海200433
  17. 海军军医大学第一附属医院呼吸与危重症医学科，上海200433
  18. 海军军医大学第一附属医院肿瘤科，上海200433
  19. 上海中医药大学附属上海市中西医结合医院肿瘤科，上海 200082
  20. 上海中医药大学附属龙华医院肿瘤科，上海 200032
  21. 上海中医药大学附属龙华医院中西医结合乳腺科，上海 200032
- 作者简介：
  
  [ "曾铖（ORCID: 0009-0005-5307-3822），硕士在读。" ]
  张剑（ORCID: 0000-0002-7890-4187），主任医师，复旦大学附属肿瘤医院Ⅰ期临床试验病房副主任。
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.11.006
  中图分类号： R730.6
- 收稿：2023-05-02，
  
  修回：2023-09-10，
  
  纸质出版：2023-11-30
- 稿件说明：
移动端阅览
曾铖, 金奕滋, 李婷, 等. 上海市癌症患者化疗所致恶心呕吐的横断面研究[J]. 中国癌症杂志, 2023,33(11):1009-1017.

Cheng ZENG, Yizi JIN, Ting LI, et al. Chemotherapy-induced nausea and vomiting among cancer patients in Shanghai: a cross-sectional study[J]. China Oncology, 2023, 33(11): 1009-1017.
曾铖, 金奕滋, 李婷, 等. 上海市癌症患者化疗所致恶心呕吐的横断面研究[J]. 中国癌症杂志, 2023,33(11):1009-1017. DOI： 10.19401/j.cnki.1007-3639.2023.11.006.

Cheng ZENG, Yizi JIN, Ting LI, et al. Chemotherapy-induced nausea and vomiting among cancer patients in Shanghai: a cross-sectional study[J]. China Oncology, 2023, 33(11): 1009-1017. DOI： 10.19401/j.cnki.1007-3639.2023.11.006.

摘要

背景与目的：

化疗所致恶心呕吐（chemotherapy-induced nausea and vomiting，CINV）可使癌症患者机体功能紊乱，甚至导致死亡。预防CINV对于接受致吐性化疗方案的患者至关重要。本研究旨在分析上海市三甲医院CINV的发生情况及处理方式，探讨与CINV相关的危险因素，以期进一步改善CINV管理。

方法：

选取2022年10月—2022年12月在上海市16家三甲医院接受治疗的376例癌症患者作为研究对象，采用问卷调查的方式开展横断面研究。使用单因素和多因素logistic回归模型分析CINV的影响因素。

结果：

2022年上海市CINV管理与指南符合率较5年前有显著改善。对于接受高致吐风险化疗方案的患者，指南符合率从21.6%提升至67.0%。对于接受中致吐风险化疗方案的患者，神经激肽-1（neurokinin-1，NK-1）受体抑制剂的使用并不能显著降低CINV的发生率。多因素分析显示，化疗方案是CINV发生的唯一独立危险因素（

0.05）。

结论：

化疗方案是影响CINV发生的独立危险因素，临床实践中应优先关注药物本身的致吐风险，做好风险评估，严格遵循指南，从而最大化地控制CINV。

Abstract

Background and purpose:

Chemotherapy-induced nausea and vomiting (CINV) can cause severe damage to body functions and even lead to death. The prevention of CINV is critically important in patients receiving emetogenic chemotherapy regimen. This study aimed to investigate the prevalence and treatment of CINV in Grade-A tertiary hospitals in Shanghai and explore risk factors of CINV to improve its management.

Methods:

The clinical data of 376 cancer patients in Grade-A tertiary hospitals in Shanghai from October 2022 to December 2022 were collected retrospectively. The questionnaire was used to conduct a cross-sectional study. The univariate and

multivariable logistic regression models were used to evaluate the influencing factors of CINV.

Results:

The management and coincidence of the guideline in 2022 significantly improved compared to five years ago. For patients receiving high-emetic-risk chemotherapy regimen

the coincidence of the guideline increased from 21.6% to 67.0%. For patients receiving moderate-emetic-risk chemotherapy regimen

the neurokinin-1 (NK-1) receptor antagonist was not significantly associated with CINV. Multivariable analysis showed that the chemotherapy regimen was the only risk factor for CINV during the whole period (

0.05).

Conclusion:

The chemotherapy regimen is the main risk factor for CINV. To control CINV better

clinical practitioners should focus on the intrinsic risk of chemotherapy regimens preferentially

estimate the risk and adhere better to guidelines.

关键词

Keywords

references

JORDAN K , JAHN F , AAPRO M . Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review [J ] . Ann Oncol , 2015 , 26 ( 6 ): 1081 - 1090 . DOI: S0923-7534(19)31811-3 http://doi.org/S0923-7534(19)31811-3

LYONS E , LINE C , LEE J J . Developing drugs for prevention of chemotherapy-induced nausea and vomiting: draft guidance from the FDA [J ] . Clin Cancer Res , 2021 , 27 ( 22 ): 6072 - 6074 . DOI: 10.1158/1078-0432.CCR-21-1941 http://doi.org/10.1158/1078-0432.CCR-21-1941 https://aacrjournals.org/clincancerres/article/27/22/6072/671741/Developing-Drugs-for-Prevention-of-Chemotherapy https://aacrjournals.org/clincancerres/article/27/22/6072/671741/Developing-Drugs-for-Prevention-of-Chemotherapy

GRASSI L , BERARDI M A , RUFFILLI F , et al . Role of psychosocial variables on chemotherapy-induced nausea and vomiting and health-related quality of life among cancer patients: a European study [J ] . Psychother Psychosom , 2015 , 84 ( 6 ): 339 - 347 . DOI: 10.1159/000431256 http://doi.org/10.1159/000431256

NATALE J J . Overview of the prevention and management of CINV [J ] . Am J Manag Care , 2018 , 24 (18 Suppl): S391 -S397.

PIECHOTTA V , ADAMS A , HAQUE M , et al . Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis [J ] . Cochrane Database Syst Rev , 2021 , 11 ( 11 ): CD012775 .

BADARUDIN N S , MOHAMED SHAH N , MOHD KASSIM K N B , et al . A retrospective study on chemotherapy-induced nausea and vomiting in highly/moderately emetogenic chemotherapy: incidence and prescribing practice [J ] . Support Care Cancer , 2022 , 30 ( 6 ): 5339 - 5349 . DOI: 10.1007/s00520-022-06956-0 http://doi.org/10.1007/s00520-022-06956-0

RAZVI Y , CHAN S , MCFARLANE T , et al . ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients [J ] . Support Care Cancer , 2019 , 27 ( 1 ): 87 - 95 . DOI: 10.1007/s00520-018-4464-y http://doi.org/10.1007/s00520-018-4464-y

上海市抗癌协会癌症康复与姑息专业委员会 . 化疗所致恶心呕吐全程管理上海专家共识(2018年版) [J ] . 中国癌症杂志 , 2018 , 28 ( 11 ): 946 - 960 .

Cancer Rehabilitation and Palliative Care Committee of Shanghai Anti-Cancer Association . Shanghai Consensus Guidelines for the Management of chemotherapy-induced nausea and vomiting (2018 edition) [J ] . Chin Oncol 2018 , 28 ( 11 ): 946 - 960 .

SUN Y , ZHENG Y Z , YANG X Y , et al . Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China [J ] . J Cancer Res Clin Oncol , 2021 , 147 ( 9 ): 2701 - 2708 . DOI: 10.1007/s00432-021-03554-1 http://doi.org/10.1007/s00432-021-03554-1

COOKSLEY T , GIROTRA M , GINEX P , et al . Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities [J ] . Support Care Cancer , 2020 , 28 ( 12 ): 6175 - 6181 . DOI: 10.1007/s00520-020-05709-1 http://doi.org/10.1007/s00520-020-05709-1

National Comprehensive Cancer Network . NCCN Guidelines Version 1. 2023 Antiemesis [EB/OL ] . ( 2023 -03-23)[2023-08-30 ] . https://www.nccn.org/guidelines. https://www.nccn.org/guidelines https://www.nccn.org/guidelines

HESKETH P J , GRUNBERG S M , GRALLA R J , et al . The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group [J ] . J Clin Oncol , 2003 , 21 : 4112 - 4119 . DOI: 10.1200/JCO.2003.01.095 http://doi.org/10.1200/JCO.2003.01.095

POLI-BIGELLI S , RODRIGUES-PEREIRA J , CARIDES A D , et al . Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America [J ] . Cancer , 2003 , 97 : 3090 - 3098 . DOI: 10.1002/cncr.v97:12 http://doi.org/10.1002/cncr.v97:12 https://acsjournals.onlinelibrary.wiley.com/toc/10970142/97/12 https://acsjournals.onlinelibrary.wiley.com/toc/10970142/97/12

BERGER M J , ETTINGER D S , ASTON J , et al . NCCN guidelines insights: antiemesis, version 2. 2017 [J ] . J Natl Compr Canc Netw , 2017 , 15 ( 7 ): 883 - 893 . DOI: 10.6004/jnccn.2017.0117 http://doi.org/10.6004/jnccn.2017.0117 https://jnccn.org/doi/10.6004/jnccn.2017.0117 https://jnccn.org/doi/10.6004/jnccn.2017.0117

许晶 , 李洁 , 张美静 , 等 . 化疗相关性恶心呕吐的回顾性研究 [J ] . 临床肿瘤学杂志 , 2018 , 23 ( 5 ): 440 - 443 .

XU J , LI J , ZHANG M J , et al . Adherence to NCCN antiemesis guideline for chemotherapy induced nausea and vomiting: a retrospective study in changhai hospital [J ] . Chin Clin Oncol , 2018 , 23 ( 5 ): 440 - 443 .

ZHANG Y X , YANG Y P , ZHANG Z H , et al . Neurokinin-1 receptor antagonist-based triple regimens in preventing chemotherapy-induced nausea and vomiting: a network meta-analysis [J ] . J Natl Cancer Inst , 2017 , 109 ( 2 ): djw217 . DOI: 10.1093/jnci/djw217 http://doi.org/10.1093/jnci/djw217 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djw217 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djw217

SEKINE I , SEGAWA Y , KUBOTA K , et al . Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis [J ] . Cancer Sci , 2013 , 104 ( 6 ): 711 - 717 . DOI: 10.1111/cas.2013.104.issue-6 http://doi.org/10.1111/cas.2013.104.issue-6 https://onlinelibrary.wiley.com/toc/13497006/104/6 https://onlinelibrary.wiley.com/toc/13497006/104/6

浏览量

2129

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

基于血管移位的诊断评分和诺莫图在鉴别颈部迷走神经鞘瘤和颈部交感神经鞘瘤中的应用

2025年美国癌症统计数据解读及对中国癌症防治工作的借鉴意义

人工智能赋能癌症协同药物组合预测的现状与挑战

2023年美国癌症数据解读及对中国癌症防治的启示

长链非编码RNA AFAP1-AS1在癌症中作用及其机制的研究进展